Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bright Minds Biosciences Inc. (DRUG) And Encourages Shareholders to Connect

accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Bright Minds Biosciences Inc. (DRUG) And Encourages Shareholders to Connect NEW YORK CITY, NY / ACCESS Newswire / November 16, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bright Minds Biosciences Inc. ("Bright Minds" or "the Company") (NASDAQ:DRUG). Investors who purchased Bright Minds securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/bright-minds-biosciences-inc-drug-investigation.

Bright Minds Investigation Details

On November 2, 2026, Bright Minds announced that the U.S. Food and Drug Administration had placed a partial clinical hold on its investigational new drug application and related protocol for a planned Phase 2 BMB-101 trial in developmental and epileptic encephalopathies. According to the Company, the FDA cited toxicity identified in mice and inadequate pharmacokinetic and juvenile-toxicity data to support proposed pediatric enrollment. The investigation concerns whether Bright Minds adequately disclosed the relevant preclinical findings and data limitations to investors.

Following this news, Bright Minds' stock price fell $28.78 per share, or approximately 52.4%, to close at $26.20 on November 2, 2026.

What's Next for Bright Minds Investors?

If you are aware of any facts relating to this investigation or purchased Bright Minds securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/bright-minds-biosciences-inc-drug-investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Bright Minds Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Bright Minds Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller

Bronstein, Gewirtz & Grossman, LLC

917-590-0911 | [email protected]

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC